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Abstract
This study demonstrated the fabrication of alginate microfibers using a modular microfluidic system for magnetic-
responsive controlled drug release and cell culture. A novel two-dimensional fluid-focusing technique with multi-inlets and
junctions was used to spatiotemporally control the continuous laminar flow of alginate solutions. The diameter of the
manufactured microfibers, which ranged from 211 mm to 364 mm, could be well controlled by changing the flow rate of the
continuous phase. While the model drug, diclofenac, was encapsulated into microfibers, the drug release profile exhibited
the characteristic of a proper and steady release. Furthermore, the diclofenac release kinetics from the magnetic iron oxide-
loaded microfibers could be controlled externally, allowing for a rapid drug release by applying a magnetic force. In
addition, the successful culture of glioblastoma multiforme cells in the microfibers demonstrated a good structural integrity
and environment to grow cells that could be applied in drug screening for targeting cancer cells. The proposed microfluidic
system has the advantages of ease of fabrication, simplicity, and a fast and low-cost process that is capable of generating
functional microfibers with the potential for biomedical applications, such as drug controlled release and cell culture.
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Introduction
Currently, most drug delivery carriers are micro-/nanoparticles
[1,2,3]. These spherical dosage forms have been studied
extensively for their drug release profiles, but some limitations
still exist. For example, they are easily expelled from the target site
and that they have a high initial burst release rate [4,5]. The
structure of the microfibers is a potentially alternative dosage form
for obtaining a controlled zero-order release profile [6]. By
providing a continuous structural integrity, microfibers can be new
carriers for delivering delicate compounds such as water soluble
drugs that have low encapsulation efficiency and reduced
bioactivity in conventional vehicles [7,8,9].
Melt spinning, wet spinning, and electrospinning are common
methods to produce microfibers [10,11,12,13]. However, melt
spinning needs bulky and heavy equipment for its high
temperature process, while wet spinning involves volatile organic
solvents, rendering them unacceptable for protein encapsulation.
The microfibers produced by electrospinning are difficult to align
directionally, and too thin to have a high enough mechanical
strength for three-dimensional (3D) scaffolds applications [14,15].
In contrast, microfluidic technology is simple, cost-effective, is
compatible with biological materials and thus an alternative
method for producing uniform micro-/nanofibers [14,16,17,18].
Numerous studies have utilized magnetic nanoparticles for
medical and biological applications, such as drug/gene delivery,
bio-separation, and magnetic resonance imaging [19,20,21,22,23].
Previous studies have demonstrated that magnetic nanoparticles
can be controlled to facilitate drug release from spherical particles
[24,25,26]. This suggests that magnetic nanoparticles can be
entrapped in microfibers. However, this kind of magnetically-
controlled release strategy has not yet been applied on microfibers.
Therefore, the aim of this study was to develop a facile way to
obtain polymer microfibers by utilizing microfluidic technology. In
order to have good control over the fabrication of the microfibers,
we used the design of multi-inlets and multi-junctions to achieve
the dispersed and the continuous phases for solidifying and
shielding the microfibers without them clogging the microchannels
[16]. The advantage of the microchannel design is that it is simple
and efficient to fabricate microfibers using a one-step continuous
process. The main novelties of this study are (i) a linear release
behavior from the diclofenac-loaded microfibers; (ii) an active
control over the drug release rate from the microfibers by exerting
magnetic iron oxide (MIO) nanoparticles; and (iii) a one-step cell
encapsulation system to culture cancer cells for screening potential
anticancer agents.
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1. Materials
Sodium alginate (cat. A2158), diclofenac sodium (cat. D6899),
calcium chloride (cat. 499609), and magnetic iron oxide (MIO)
nanoparticles (cat. 725331) were purchased from Sigma-Aldrich
Co. (St. Louis, MO). Sunflower seed oil was obtained from Uni-
President Enterprise Co. (Taiwan). De-ionized water was prepared
using a Milli-QH system (Millipore Inc., Clifton, NJ). Glioblastoma
Multiforme (GBM) cells used in the present study were obtained
from the Bioresource Collection and Research Center (BCRC) in
Taiwan. All other reagents were commercially available and of
analytical grade.
2. Design and fabrication of a microfluidic chip
The microfluidic chip was designed by AutoCADH 2007
(Autodesk, USA). The CAD data was then fed to a computer-
controlled CO2 laser machine (LaserPro Venus, GCC, Taiwan)
for the laser micromachining process and laid out on a
Figure 1. Microfluidic chip. Expanded view (A) and a photo (B) of the microfluidic chip: 1, inlets of center channels; 2 and 3, inlets of side channels;
4, cross junction; 5, outlet; 6, observation channel; 7, bottom layer disk; 8, screw orifices; 9, the scale bar=11 cm. (C) is the geometry of the
microfluidic channels.
doi:10.1371/journal.pone.0033184.g001
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width/depth: 270/210/1.5 mm) [27,28,29,30,31]. As shown in
the expanded view of Fig. 1A, the microfluidic chip consists of
three layers (length/width/depth: 110/45/4.5 mm) which includ-
ed, from top to bottom: the cover layer (with reagent inlet), the
channel layer (cross-junction microchannels) and the bottom layer
(with product outlet), respectively. These three layers were held
together by twenty-nine M4 screws, and were tightened at
1,1.2 Nm using an adjustable torque wrench. The microfluidic
chip has five inlets (three for the center channels and two for the
side channels), two cross junctions and one outlet, as shown in
Fig. 1B. The broadened channel near the outlet is the observation
channel which was designed for slowing down the flow and
enhancing the observation of the analysis (Fig. 1C). There are
three types of downstream channels (300, 350 and 400 mm,
respectively) in this study
3. Manufacturing procedure of microfibers
The dispersed phase was composed of 2 wt. % CaCl2, deionized
water, and 1 wt. % alginate solutions. In order to enhance
observation of the synthesized microfibers, we incorporated 0.1 wt.
% Rhodamine B in the alginate solution in some of the
experiments. As shown in Fig. 2, the alginate and CaCl2 solutions
were injected into two of the central side channels, respectively,
and sandwiched the deionized water thereby retarding the gelling
of the alginate at the first junction. The sunflower seed oil as the
continuous phase was delivered from two side channels at the
second junction. All solutions were connected to the microfluidic
platform by Teflon tubing with an I.D. of 0.76 mm, an O.D. of
1.22 mm, and a length of 400 mm. Simultaneous injection of the
dispersed and continuous phases into the microfluidic chip was
carried out by individual digitally controlled syringe pumps
(KDS230, KD Scientific, USA). By tuning the flow rates of the
dispersed and continuous phases, the microfiber could be
synthesized. The microfibers fabricated in the collected reservoir
beneath the outlet of the microfluidic chip were retrieved for
further examination (Text S1). The stability of the microfibers
under different pH conditions was described in the Text S2
(please see Fig. S1 about microscopic images of the microfibers).
4. Release behavior of the diclofenac-loaded microfibers
with/without MIO nanoparticles
Diclofenac was used as the model drug to estimate the drug
release behavior of the microfiber. To enhance and to control the
release efficiency of the microfibers, MIO nanoparticles with an
average 5 nm particle size were loaded into the microfiber. The
alginate solution consisted of 1 wt. % alginate, 1 wt. % diclofenac
sodium, and 4 wt. % MIO nanoparticles. The encapsulation
efficiency (EF) of the MIO nanoparticles detected by inductively
coupled plasma mass spectrometry was determined indirectly
according to the literature [32]. The amount of MIO nanopar-
ticles entrapped in the microfibers was calculated by the difference
between the total amount used to prepare the systems and the
amount of MIO nanoparticles that remained in the aqueous phase
after isolating the microfibers.
EF~ totalamountof MIO{freeMIOinsupernatant ðÞ
=totalamountof MIO|100%
In the release study, 0.1 g manufactured microfibers containing
diclofenac and MIO nanoparticles were dispersed in 1 mL pH 7.4
and 37uC water solutions. The proposed release system was
conducted on an orbital shaker at a constant shaking of 100 rpm.
An external magnetic field, 0.4 Tesla (T) at the border of the
magnet, was applied on the sample by a 0.5 cm distance at
determined times as the release experiment was carried out. At
pre-determined time intervals, 10 mL solutions were drawn to
determine the concentration of diclofenac by high-performance
liquid chromatography (HPLC) analysis (L2000 system, Hitachi,
Japan).
Figure 2. Microfiber formation. The diagram of the microfluidic system and photographs of observation positions. 1, 2 wt % CaCl2 solution; 2,
deionized water; 3, alginate solution; 4, sunflower seed oil; 5, observation channel; 6, microfibers. The formation of microfibers: A, photograph of the
microfiber in the observation channel; B, Photograph of the second cross junction; C, photograph of the first cross junction.
doi:10.1371/journal.pone.0033184.g002
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The characteristics of biocompatibility, biodegradability, high
water content, and tissue-like elasticity make alginate an ideal
candidate for scaffolds when growing cells and tissues. Similar to
the process of preparing diclofenac-loaded microfibers, 1.65610
5
cells/mL GBM cells were used as model cells to be encapsulated in
microfibers for studying the cell culture in vitro. The GBM cell-
contained microfibers were cultured in Dulbecco’s modified media
(DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS)
at 37uC with 5% CO2 in a humidified incubator. At pre-
determined times, the GBM cells in the microfibers were observed
through the microscope.
Results and Discussion
1. Principle of the formation of microfibers
Based on the external crosslinking process of alginate [33], we
created a microfluidic system to control the spontaneous self-
assembly of alginate microfibers. As shown in Fig. 2, the
components of the dispersed phase, containing a CaCl2 gelating
solution, deionized water, and a sodium alginate solution, were
injected into the microchannels individually. Sodium alginate was
crosslinked and then solidified to calcium alginate by diffusion of
the Ca
2+ ions to exchange sodium ions from the guluronic acids
with the divalent cations [33]. The design of three-in dispersed
phase has the advantage that it makes it easy to control the three
individual injections to solidify alginate microfibers by gradual
extrusion without clogging. After the components of the dispersed
phase were mixed, the microfiber formed. The continuous oil
phase then shielded the microfiber after the second junction to
prevent aggregation on the channel wall.
2. Synthesis of microfibers
Alginate, commonly extracted from brown algae, is a natural
biopolymer and advantageous by being non-immunogenic,
biocompatible, and able to dissolve and degrade under physio-
logical conditions [34,35]. It is one of the most employed and
recognized material for the applications of drug delivery and cell
encapsulation [36,37,38]. Alginate can be cross-linked by divalent
cations to form gel structures as requested, and this tailor-made
property makes it advantageous as a formulation aid. A dispersed
phase consisting of CaCl2, deionized water and alginate solutions
was delivered into the three center channels to generate alginate
microfibers. As shown in Fig. 2, the CaCl2 (stained with
methylene blue) and alginate solutions (stained with Rhodamine
B - red color) were separated by water, which allowed the
formation of microfibers to occur without immediate gelation. It
was found that the three solutions of the dispersed phase resulted
Figure 3. Microfiber images. Microscopic images (A,B, stained with Rhodamine B) and scanning electron microscopy images (C,E) of
microfibers.
doi:10.1371/journal.pone.0033184.g003
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then compressed by the sheath force of the oil at the second cross
junction (Fig. 2B); meanwhile the Na
+ ions from the sodium
alginate were exchanged by Ca
2+ ions, resulting in the formation
of cross-linked alginate microfibers (Fig. 2A). The microfibers
formed continuously without breaking off in the chip micro-
channels (Fig. 3A), and further gelation was not needed. The
resulting microfibers were cylindrical with a uniform diameter
(Fig. 3B). Scanning electron microscope (SEM) analysis of
microfibers revealed that the surface of the microfibers appeared
to have bundle-cluster morphology (Fig. 3C–D).
This microfluidic platform successfully manufactured alginate
microfibers for the applications mentioned below. The proposed
microfluidic chip features a design of multi-inlets and multi-
junctions that deliver immiscible phases to solidify and shield the
alginate microfibers continuously and smoothly without breaking
off or clogging.
3. Influence of flow rates and observation channel width
on fiber size
To further understand the process we studied the relationships
among the microfiber diameter, the flow speed of the continuous
phase (sunflower oil) and the width of the observation channel. As
shown in Table 1, the diameter of the microfibers decreased from
364.3616.3 to 205.365.7 mm when the flow speed of the
continuous phase increased from 1 to 5 mL/min with an
observation channel width of 0.3 mm. The same phenomenon
was noted at observation channels with widths of 0.35 and
0.4 mm, respectively, indicating that the higher flow speed of the
continuous phase results in significantly narrower microfibers
(ANOVA test, p,0.01). Exploring the effects of the observation
channel on the microfiber size revealed that there were no
significant differences (ANOVA test, p.0.05) among the diame-
ters of the microfibers obtained from different channel widths
(0.3,0.4 mm) at the same flow speed of the continuous phase.
The above mentioned results show that the flow speed of the
continuous phase was an effective factor for the diameter of the
microfibers, and can be used as a control parameter. However, the
effect of the channel width was less pronounced than that of the
flow speed of the continuous phase. Equations (1), (2), and (3)
represent the relationships between the diameter of the microfibers
and the flow speed of the continuous phase with the channel width
of 0.3, 0.35 and 0.4 mm, respectively.
D~178:4z 191:3=F ðÞ ,R2~0:98, ð1Þ
D~159:5z 190:1=F ðÞ ,R2~0:94, ð2Þ
D~186:1z 162:3=F ðÞ ,R2~0:94, ð3Þ
where D=the diameter (mm), and F=the flow rate (mL/hour).
In addition, we studied the effects of the dispersed phase flow
rate on the size of the microfibers. As shown in Table 2, the
microfiber diameter increases with the dispersed phase flow rate,
agreeing with previous literatures [16,39]. The small relative
standard deviation reflects the good uniformity of alginate
microfibers obtained under each flow condition.
4. In vitro release of diclofenac
Diclofenac is a widely used non-steroidal anti-inflammatory
drugs (NSAIDs) for local and systemic administration. A stable
drug delivery rate can reduce dose-related adverse effects caused
by the NSAIDs, such as gastrointestinal complications [40,41]. To
monitor the drug release behavior of the alginate microfibers,
diclofenac was encapsulated in the microfibers for the release
Table 1. The relationships among the diameter of
microfibers, width of observation channel and flow rate of
continuous phase.
Observation
channel
width
(mm)
Continuous
phase
(mL/min) Microfiber diameter (mm)
Average size RSD
0.3 1 364.3 16.3
2 287.1 8.1
3 245.4 9.2
4 226.9 12.3
5 205.3 5.7
0.35 1 341.0 5.7
2 276.3 14.1
3 230.0 10.7
4 208.3 8.0
5 177.4 2.5
0.4 1 345.7 9.6
2 273.1 8.0
3 242.3 7.1
4 228.4 7.1
5 211.4 7.1
doi:10.1371/journal.pone.0033184.t001
Table 2. The relationships between the diameter of the microfiber and the flow rate of the dispersed phase.
Observation
channel width (mm)
Continuous phase
(mL/min) Dispersed phase (mL/min) Microfiber diameter (mm)
alginate CaCl2 water Average size RSD
0.35 1 0.02 0.24 0.24 285.1 4.4
0.04 0.45 0.45 323.9 5.8
0.08 0.90 0.90 387.5 5.6
doi:10.1371/journal.pone.0033184.t002
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first investigated the magnetism of the as-prepared microfibers
containing magnetic nanoparticles. Fig. 4A shows the magneti-
zation curve of the as-prepared microfibers as a function of the
applied fields at 300 K. The saturation magnetization value of the
microfibers is above 8 emu/g microfiber. As shown in Fig. 4B, the
release of diclofenac from the microfibers without magnetic force
was used as the control group. The release profile was
approximately a linear release, and up to 91.962.8% of the
encapsulated diclofenac was emptied after 1.5 hours. This
indicated that the microfibers exhibited an excellent advantage
as drug delivery carriers over the common microparticles which
suffer from excessive initial burst release [4,5]. The approximate
zero-order release pattern of the microfibers offered a steady
sustained release for pharmaceutical applications.
Except for leaking out of the microfibers by passive diffusion,
the suitable active control approach of drug release can broaden
the microfibers applications. The in vitro release data in triplicate
shown in Fig. 4B reveals that the drug release profile of the
resulting microfibers is controllable by a specific magnetic field.
When applying a magnetic force from the beginning or at the 20
th
minute for 10 minutes, 98.162.9% and 96.563.0% diclofenac
released from microfibers at the 40
th minute, respectively. These
two fast release rates are due to the fact that the MIO
nanoparticles in the microfibers were attracted by the magnetic
force and made the microfibers more porous. When applying the
same magnetic force at the 10
th,3 0
th and 60
th minute for
Figure 4. Characteristics of the microfibers. (A) The hysteresis curve of the microfibers containing MIO nanoparticles. (B) Release profiles of
diclofenac from MIO-loaded microfibers without magnetic stimulation as the control (n), with 2 minutes stimulation at the 10th, 30th and 60th
minute (m), with a 10-minute stimulation after the 20th minutes (N) and with a continuous stimulation from the beginning (#).
doi:10.1371/journal.pone.0033184.g004
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applied. This result show that the microfibers encapsulating MIO
nanoparticles were well made and that the release of drugs from
the microfibers was enhanced and could be controlled externally.
Therefore, fabricated microfibers can offer an advantage over
conventional drug delivery devices by providing an improved
dosing precision, ease of operation, and better compliance.
The encapsulation efficiencies of both diclofenac and the MIO
nanoparticles were greater than 90%. The drug loading efficiency
of external gelation depends on the material properties of the
matrix substrate. The encapsulation efficiency of this proposed
microfluidic method is similar to that of the traditional external
gelation method [42]. Generally speaking, when the same material
(alginate) is employed, a similar encapsulation efficiency is
obtained.
5. Encapsulation of GBM cells
In addition to molecular drugs, microfibers can also encapsulate
tumor cells for drug screening applications. The cell culture in the
hollow fiber assay (HFA) developed by the US National Cancer
Institute was proven to be a hastening method for screening
potential anticancer agents [43,44]. Our microfluidic system
provided a one-step cell filling platform that saves a lot of human
labor compared to the traditional HFA method, including
tediously repeating flushing processes of solutions and cells
[43,44]. In the present study, GBM, which is the most common
and lethal type of brain cancer [45], was chosen to demonstrate
cell culture in the microfibers for drug screening to target cancer
cells [46]. The GBM-loaded microfibers were cultured directly
after the microfiber fabrication process. Because the microfluidic
encapsulation process was mild and cell friendly, GBM cells
(Fig. 5A) seemed not to be affected greatly by this manufacturing
process and could adhere well to the microfibers (Fig. 5B)t o
undergo proliferation (Fig. 5C & 5D). It was evident that the
GBM cells were arranged in tube-like structures and that direct
cell to cell contact took place. The cell proliferation in the
microfibers went with the culture time (Fig. 5C & 5D). The
results demonstrated that the microfibers can provide a good
environment for culturing cells. In addition to loading tumor cells
for drug screening applications, these microfibers can also
encapsulate cells for numerous tissue engineering or therapeutic
applications such as nerve conduits, protection from immune
rejection (immunoisolation) and for a bioreactor [47,48,49].
This study successfully proposed a simple microfluidic system
for fabricating sophisticated microfibers. The diameter of these
microfibers, ranging from 177.4 mm to 364.3 mm, could be easily
controlled by regulating the flow rate and channel size. The
diclofenac-loaded microfibers appeared to have a zero-order drug
release, and this release rate could be actively controlled by
applying magnetic iron oxide nanoparticles. The successful culture
of Glioblastoma Multiforme cells verified that microfibers from this
microfluidic system could provide a good environment for cell
culture and tissue engineering applications.
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the 1st day; D. GBM in microfibers at the 7th day. Arrows indicate GBM cells.
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